| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Body Mass Index (BMI) Small Decrease | Improves (the measure goes down) | Small effect | 586 people | |||
| Weight | Improves (the measure goes down) | 3 studies | 614 people | |||
| Hip Circumference | Improves (the measure goes down) | 151 people | ||||
| Waist circumference | Improves (the measure goes down) | 349 people | ||||
| Waist-Hip Ratio | Improves (the measure goes up) | 162 people |
Supplement
Resveratrol is a plant compound found in grape skins and berries that works as an antioxidant and calms inflammation. People mostly look at it for kidney health, and the evidence is moderate: blood urea nitrogen, a waste marker the kidneys clear, went down, and inflammatory bowel disease symptoms improved in one trial. Those studies were small, though, and the bowel result rests on just 105 people.
Sources: PMID 33960587
- Updated
- How we grade
- 52 studies cited
- Best evidence
- Grade B
- Conditions studied
- 43
- Outcomes
- 318
- Graded outcomes
- 017810
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Blood glucose Small Improvement | Improves (the measure goes down) | Small effect | 7 studies | 329 people | ||
Studies that measured blood glucose
| ||||||
| Adiponectin Small Increase | Improves (the measure goes up) | Small effect | 2,474 people | |||
| C-Reactive Protein (CRP) | Improves (the measure goes down) | 3 studies | 147 people | |||
Studies that measured c-reactive protein (crp)
| ||||||
| Weight | Improves (the measure goes down) | 3 studies | 1,265 people | |||
Studies that measured weight
| ||||||
| Kidney Function | Improves (the measure goes up) | 2 studies | 135 people | |||
Studies that measured kidney function | ||||||
| Liver Enzymes | Changes; see studies | 2 studies | 216 people | |||
| Oxidative Stress Biomarkers | Improves (the measure goes down) | 2 studies | 552 people | |||
| Total cholesterol | Improves (the measure goes down) | 2 studies | 187 people | |||
| Vascular Function | Improves (the measure goes up) | 2 studies | 1,448 people | |||
| Blood Pressure | Improves (the measure goes down) | 1 study | 792 people | |||
| Glycemic Control | Improves (the measure goes up) | 1 study | 29 people | |||
| Triglycerides | Improves (the measure goes down) | 1 study | 976 people | |||
| Blood Urea Nitrogen (BUN) | Improves (the measure goes up) | 894 people | ||||
| Body Fat | Improves (the measure goes down) | 516 people | ||||
| Body Mass Index (BMI) | Improves (the measure goes down) | 1,418 people | ||||
| HbA1c | Improves (the measure goes down) | 271 people | ||||
| High-density lipoprotein (HDL) | Improves (the measure goes up) | 837 people | ||||
| Insulin | Changes; see studies | 172 people | ||||
| Insulin Resistance | Improves (the measure goes down) | 191 people | ||||
| Intercellular Adhesion Molecule 1 | Changes; see studies | 1,034 people | ||||
| Interleukin 6 | Improves (the measure goes down) | 225 people | ||||
| Low-density lipoprotein (LDL) | Improves (the measure goes down) | 205 people | ||||
| Plasminogen Inhibitor-1 | Improves (the measure goes up) | 1,034 people | ||||
| Serum Albumin | Improves (the measure goes up) | 516 people | ||||
| Superoxide Dismutase Activity | Improves (the measure goes up) | 118 people | ||||
| TNF-Alpha | Improves (the measure goes down) | 483 people | ||||
| Uric Acid | Improves (the measure goes down) | 353 people | ||||
| Waist circumference | Improves (the measure goes down) | 459 people | ||||
Overweight
- Blood glucose: improves
- Weight: improves
- Vascular Function: improves
Chronic Kidney Disease (CKD)
- Blood glucose: improves
- C-Reactive Protein (CRP): improves
- Kidney Function: improves
Stable Angina
- C-Reactive Protein (CRP): improves
- Interleukin 6: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| C-Reactive Protein (CRP) Small Decrease | Improves (the measure goes down) | Small effect | 3 studies | 147 people | ||
Studies that measured c-reactive protein (crp)
| ||||||
| Interleukin 6 | Improves (the measure goes down) | 225 people | ||||
General Cardiovascular Health
- Blood Pressure: improves
- Vascular Function: improves
- Exercise Adaptations: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Blood Pressure Small Improvement | Improves (the measure goes down) | Small effect | 1 study | 1,648 people | ||
Studies that measured blood pressure | ||||||
| Vascular Function | Improves (the measure goes up) | 2 studies | 268 people | |||
Studies that measured vascular function
| ||||||
| Exercise Adaptations | Improves (the measure goes up) | 1 study | 27 people | |||
Studies that measured exercise adaptations | ||||||
| Exercise-Induced Oxidation | Changes; see studies | 27 people | ||||
Inflammatory Bowel Disease (IBD)
- Inflammatory Bowel Disease Symptoms: improves
- Quality of Life: improves
- Ulcerative Colitis Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Inflammatory Bowel Disease Symptoms Small Improvement | Improves (the measure goes down) | Small effect | 1 study | 105 people | ||
Studies that measured inflammatory bowel disease symptoms | ||||||
| Quality of Life | Improves (the measure goes up) | 105 people | ||||
| Ulcerative Colitis Symptoms | Improves (the measure goes down) | 105 people | ||||
Ulcerative Colitis
- Inflammatory Bowel Disease Symptoms: improves
- Quality of Life: improves
- Ulcerative Colitis Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Inflammatory Bowel Disease Symptoms Small Improvement | Improves (the measure goes down) | Small effect | 1 study | 105 people | ||
Studies that measured inflammatory bowel disease symptoms | ||||||
| Quality of Life | Improves (the measure goes up) | 105 people | ||||
| Ulcerative Colitis Symptoms | Improves (the measure goes down) | 105 people | ||||
Nonalcoholic Fatty Liver Disease (NAFLD)
- Adiponectin: improves
- Blood glucose: improves
- C-Reactive Protein (CRP): improves
Metabolic Syndrome
- Adiponectin: improves
- Blood glucose: improves
- C-Reactive Protein (CRP): improves
Osteoarthritis (OA)
- Blood Urea Nitrogen (BUN): improves
- Kidney Function: improves
- Pain: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Blood Urea Nitrogen (BUN) Small Decrease | Improves (the measure goes down) | Small effect | 894 people | |||
| Kidney Function | Improves (the measure goes up) | 2 studies | 135 people | |||
Studies that measured kidney function | ||||||
| Pain | Improves (the measure goes down) | 1 study | 142 people | |||
Studies that measured pain | ||||||
| Osteoarthritis Symptoms | Improves (the measure goes down) | 142 people | ||||
| Serum Albumin | Improves (the measure goes up) | 516 people | ||||
| Uric Acid | Improves (the measure goes down) | 353 people | ||||
Chronic Obstructive Pulmonary Disease (COPD)
- Blood Urea Nitrogen (BUN): improves
- Kidney Function: improves
- Serum Albumin: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Blood Urea Nitrogen (BUN) Small Decrease | Improves (the measure goes down) | Small effect | 894 people | |||
| Kidney Function | Improves (the measure goes up) | 2 studies | 135 people | |||
Studies that measured kidney function | ||||||
| Serum Albumin | Improves (the measure goes up) | 516 people | ||||
| Uric Acid | Improves (the measure goes down) | 353 people | ||||
Body Composition
- Body Mass Index (BMI): improves
- Weight: improves
- Hip Circumference: improves
Dyslipidemia
- Adiponectin: improves
- Weight: improves
- Total cholesterol: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Adiponectin Small Increase | Improves (the measure goes up) | Small effect | 285 people | |||
| Weight | Improves (the measure goes down) | 3 studies | 582 people | |||
| Total cholesterol | Improves (the measure goes down) | 2 studies | 863 people | |||
| Glycemic Control | Improves (the measure goes up) | 1 study | 541 people | |||
| Body Fat | Improves (the measure goes down) | 1,171 people | ||||
| HbA1c | Improves (the measure goes down) | 444 people | ||||
| High-density lipoprotein (HDL) | Improves (the measure goes up) | 793 people | ||||
| Leptin | Improves (the measure goes up) | 271 people | ||||
| Low-density lipoprotein (LDL) | Improves (the measure goes down) | 791 people | ||||
| Waist circumference | Improves (the measure goes down) | 335 people |
Heart Failure
- Blood Urea Nitrogen (BUN): improves
- Kidney Function: improves
- Serum Albumin: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Blood Urea Nitrogen (BUN) Small Decrease | Improves (the measure goes down) | Small effect | 894 people | |||
| Kidney Function | Improves (the measure goes up) | 2 studies | 135 people | |||
| Serum Albumin | Improves (the measure goes up) | 516 people | ||||
| Uric Acid | Improves (the measure goes down) | 353 people |
Hepatic Encephalopathy
- Blood Urea Nitrogen (BUN): improves
- Kidney Function: improves
- Serum Albumin: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Blood Urea Nitrogen (BUN) Small Decrease | Improves (the measure goes down) | Small effect | 894 people | |||
| Kidney Function | Improves (the measure goes up) | 2 studies | 135 people | |||
| Serum Albumin | Improves (the measure goes up) | 516 people | ||||
| Uric Acid | Improves (the measure goes down) | 353 people |
Kidney Health
- Blood Urea Nitrogen (BUN): improves
- Kidney Function: improves
- Serum Albumin: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Blood Urea Nitrogen (BUN) Small Decrease | Improves (the measure goes down) | Small effect | 894 people | |||
| Kidney Function | Improves (the measure goes up) | 2 studies | 135 people | |||
| Serum Albumin | Improves (the measure goes up) | 516 people | ||||
| Uric Acid | Improves (the measure goes down) | 353 people |
High Blood Pressure
- Blood glucose: improves
- C-Reactive Protein (CRP): improves
- Kidney Function: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Blood glucose Small Improvement | Improves (the measure goes down) | Small effect | 7 studies | 871 people | ||
| C-Reactive Protein (CRP) | Improves (the measure goes down) | 3 studies | 658 people | |||
| Kidney Function | Improves (the measure goes up) | 2 studies | 135 people | |||
| Total cholesterol | Improves (the measure goes down) | 2 studies | 871 people | |||
| Vascular Function | Improves (the measure goes up) | 2 studies | 1,448 people | |||
| Blood Pressure | Improves (the measure goes down) | 1 study | 1,448 people | |||
| Blood Urea Nitrogen (BUN) | Improves (the measure goes up) | 894 people | ||||
| Insulin | Changes; see studies | 871 people | ||||
| Insulin Resistance | Improves (the measure goes down) | 871 people | ||||
| Intercellular Adhesion Molecule 1 | Changes; see studies | 1,034 people | ||||
| Interleukin 6 | Improves (the measure goes down) | 658 people | ||||
| Low-density lipoprotein (LDL) | Improves (the measure goes down) | 871 people | ||||
| Plasminogen Inhibitor-1 | Improves (the measure goes up) | 1,034 people | ||||
| Serum Albumin | Improves (the measure goes up) | 516 people | ||||
| TNF-Alpha | Improves (the measure goes down) | 658 people | ||||
| Uric Acid | Improves (the measure goes down) | 353 people |
Periodontitis
- Blood glucose: improves
- Total cholesterol: improves
- Blood Pressure: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Blood glucose Small Improvement | Improves (the measure goes down) | Small effect | 7 studies | 871 people | ||
| Total cholesterol | Improves (the measure goes down) | 2 studies | 871 people | |||
| Blood Pressure | Improves (the measure goes down) | 1 study | 871 people | |||
| Insulin | Changes; see studies | 871 people | ||||
| Insulin Resistance | Improves (the measure goes down) | 871 people | ||||
| Low-density lipoprotein (LDL) | Improves (the measure goes down) | 871 people |
Coronary Artery Disease (CAD)
- Blood Flow: improves
- Blood glucose: improves
- C-Reactive Protein (CRP): improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Blood Flow Small Increase | Improves (the measure goes up) | Small effect | 1 study | 40 people | ||
| Blood glucose | Improves (the measure goes down) | 7 studies | 871 people | |||
| C-Reactive Protein (CRP) | Improves (the measure goes down) | 3 studies | 147 people | |||
| Total cholesterol | Improves (the measure goes down) | 2 studies | 911 people | |||
| Vascular Function | Improves (the measure goes up) | 2 studies | 1,034 people | |||
| Blood Pressure | Improves (the measure goes down) | 1 study | 871 people | |||
| High-density lipoprotein (HDL) | Improves (the measure goes up) | 40 people | ||||
| Insulin | Changes; see studies | 871 people | ||||
| Insulin Resistance | Improves (the measure goes down) | 871 people | ||||
| Intercellular Adhesion Molecule 1 | Changes; see studies | 1,034 people | ||||
| Interleukin 6 | Improves (the measure goes down) | 225 people | ||||
| Left Ventricular Ejection Fraction | Improves (the measure goes up) | 40 people | ||||
| Low-density lipoprotein (LDL) | Improves (the measure goes down) | 911 people | ||||
| Plasminogen Inhibitor-1 | Improves (the measure goes up) | 1,034 people | ||||
| TNF-Alpha | Improves (the measure goes down) | 658 people |
Polycystic Ovary Syndrome (PCOS)
- Acne Symptoms: improves
- C-Reactive Protein (CRP): improves
- Weight: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Acne Symptoms Moderate Improvement | Improves (the measure goes down) | Moderate effect | 1 study | 169 people | ||
| C-Reactive Protein (CRP) | Improves (the measure goes down) | 3 studies | 148 people | |||
| Weight | Improves (the measure goes down) | 3 studies | 1,265 people | |||
| Kidney Function | Improves (the measure goes up) | 2 studies | 135 people | |||
| Testosterone | Improves (the measure goes up) | 2 studies | 169 people | |||
| Total cholesterol | Improves (the measure goes down) | 2 studies | 108 people | |||
| Vascular Function | Improves (the measure goes up) | 2 studies | 1,034 people | |||
| Triglycerides | Improves (the measure goes down) | 1 study | 169 people | |||
| Blood Urea Nitrogen (BUN) | Improves (the measure goes up) | 894 people | ||||
| Body Fat | Improves (the measure goes down) | 516 people | ||||
| Body Mass Index (BMI) | Improves (the measure goes down) | 1,418 people | ||||
| DHEAS | Improves (the measure goes up) | 108 people | ||||
| Excessive Hair Growth | Improves (the measure goes up) | 169 people | ||||
| Fertility | Improves (the measure goes up) | 218 people | ||||
| Follicle-Stimulating Hormone | Improves (the measure goes up) | 169 people | ||||
| High-density lipoprotein (HDL) | Improves (the measure goes up) | 169 people | ||||
| Intercellular Adhesion Molecule 1 | Changes; see studies | 1,034 people | ||||
| Low-density lipoprotein (LDL) | Improves (the measure goes down) | 169 people | ||||
| Luteinizing Hormone | Improves (the measure goes up) | 169 people | ||||
| Plasminogen Inhibitor-1 | Improves (the measure goes up) | 1,034 people | ||||
| Prolactin | Improves (the measure goes up) | 387 people | ||||
| Serum Albumin | Improves (the measure goes up) | 516 people | ||||
| Sex Hormone Binding Globulin | Improves (the measure goes up) | 108 people | ||||
| Thyroid-Stimulating Hormone | Improves (the measure goes up) | 139 people | ||||
| Uric Acid | Improves (the measure goes down) | 353 people | ||||
| Waist circumference | Improves (the measure goes down) | 753 people |
High Cholesterol
- Blood Flow: improves
- C-Reactive Protein (CRP): improves
- Total cholesterol: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Blood Flow Small Increase | Improves (the measure goes up) | Small effect | 1 study | 40 people | ||
| C-Reactive Protein (CRP) | Improves (the measure goes down) | 3 studies | 40 people | |||
| Total cholesterol | Improves (the measure goes down) | 2 studies | 40 people | |||
| High-density lipoprotein (HDL) | Improves (the measure goes up) | 40 people | ||||
| Low-density lipoprotein (LDL) | Improves (the measure goes down) | 40 people |
Cognitive Improvement
- Cerebral Blood Flow: improves
- Cognition: improves
- Fatigue Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Cerebral Blood Flow Small Increase | Improves (the measure goes up) | Small effect | 9 people | |||
| Cognition | Improves (the measure goes up) | 9 people | ||||
| Fatigue Symptoms | Improves (the measure goes down) | 9 people |
Peripheral Arterial Disease
- Intercellular Adhesion Molecule 1: improves
- Vascular Function: improves
- Plasminogen Inhibitor-1: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Intercellular Adhesion Molecule 1 Small Decrease | Improves (the measure goes down) | Small effect | 1,034 people | |||
| Vascular Function | Improves (the measure goes up) | 2 studies | 1,034 people | |||
| Plasminogen Inhibitor-1 | Improves (the measure goes up) | 1,034 people |
Lower Respiratory Tract Infection
- Upper Respiratory Tract Infection Risk
- Upper Respiratory Tract Infection Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Upper Respiratory Tract Infection Risk No effect | NoneNo effect | 1 study | 39 people | |||
| Upper Respiratory Tract Infection Symptoms | Improves (the measure goes down) | 39 people |
Respiratory Health
- Upper Respiratory Tract Infection Risk
- Upper Respiratory Tract Infection Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Upper Respiratory Tract Infection Risk No effect | NoneNo effect | 1 study | 39 people | |||
| Upper Respiratory Tract Infection Symptoms | Improves (the measure goes down) | 39 people |
Upper Respiratory Tract Infection
- Upper Respiratory Tract Infection Risk
- Upper Respiratory Tract Infection Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Upper Respiratory Tract Infection Risk No effect | NoneNo effect | 1 study | 39 people | |||
| Upper Respiratory Tract Infection Symptoms | Improves (the measure goes down) | 39 people |
Obesity
- Bilirubin
- Blood glucose: improves
- C-Reactive Protein (CRP): improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Bilirubin No effect | NoneNo effect | 208 people | ||||
| Blood glucose | Improves (the measure goes down) | 7 studies | 329 people | |||
| C-Reactive Protein (CRP) | Improves (the measure goes down) | 3 studies | 869 people | |||
| Weight | Improves (the measure goes down) | 3 studies | 1,265 people | |||
| Kidney Function | Improves (the measure goes up) | 2 studies | 135 people | |||
| Liver Enzymes | Changes; see studies | 2 studies | 714 people | |||
| Vascular Function | Improves (the measure goes up) | 2 studies | 1,448 people | |||
| Blood Pressure | Improves (the measure goes down) | 1 study | 1,448 people | |||
| Glycemic Control | Improves (the measure goes up) | 1 study | 11 people | |||
| Triglycerides | Improves (the measure goes down) | 1 study | 11 people | |||
| Blood Urea Nitrogen (BUN) | Improves (the measure goes up) | 894 people | ||||
| Body Fat | Improves (the measure goes down) | 516 people | ||||
| Body Mass Index (BMI) | Improves (the measure goes down) | 1,418 people | ||||
| HbA1c | Improves (the measure goes down) | 271 people | ||||
| Insulin | Changes; see studies | 172 people | ||||
| Insulin Resistance | Improves (the measure goes down) | 191 people | ||||
| Intercellular Adhesion Molecule 1 | Changes; see studies | 1,034 people | ||||
| Interleukin 6 | Improves (the measure goes down) | 631 people | ||||
| Metabolic Rate | Improves (the measure goes up) | 11 people | ||||
| Plasminogen Inhibitor-1 | Improves (the measure goes up) | 1,034 people | ||||
| Serum Albumin | Improves (the measure goes up) | 516 people | ||||
| Superoxide Dismutase Activity | Improves (the measure goes up) | 118 people | ||||
| TNF-Alpha | Improves (the measure goes down) | 483 people | ||||
| Uric Acid | Improves (the measure goes down) | 353 people | ||||
| Waist circumference | Improves (the measure goes down) | 753 people |
Alzheimer’s Disease
- Body Fat
- Weight: improves
- Body Mass Index (BMI): improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Body Fat No effect | NoneNo effect | 516 people | ||||
| Weight | Improves (the measure goes down) | 3 studies | 1,265 people | |||
| Body Mass Index (BMI) | Improves (the measure goes down) | 1,418 people | ||||
| Waist circumference | Improves (the measure goes down) | 753 people |
Chronic Liver Disease
- Bilirubin
- Liver Enzymes: changes; see studies
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Bilirubin No effect | NoneNo effect | 208 people | ||||
| Liver Enzymes | Changes; see studies | 2 studies | 714 people |
General Liver Health
- Bilirubin
- Liver Enzymes: changes; see studies
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Bilirubin No effect | NoneNo effect | 208 people | ||||
| Liver Enzymes | Changes; see studies | 2 studies | 714 people |
Schizophrenia
- Body Fat
- Weight: improves
- Body Mass Index (BMI): improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Body Fat No effect | NoneNo effect | 516 people | ||||
| Weight | Improves (the measure goes down) | 3 studies | 1,265 people | |||
| Body Mass Index (BMI) | Improves (the measure goes down) | 1,418 people | ||||
| Waist circumference | Improves (the measure goes down) | 753 people |
Alcoholic Hepatitis
- Bilirubin
- Liver Enzymes: changes; see studies
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Bilirubin No effect | NoneNo effect | 208 people | ||||
| Liver Enzymes | Changes; see studies | 2 studies | 714 people |
Alzheimer’s Disease
- Body Fat
- Weight: changes; see studies
- Body Mass Index (BMI): changes; see studies
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Body Fat No effect | NoneNo effect | 516 people | ||||
| Weight | Changes; see studies | 3 studies | 1,265 people | |||
| Body Mass Index (BMI) | Changes; see studies | 1,418 people | ||||
| Waist circumference | Changes; see studies | 753 people |
Acne
- Acne Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Acne Symptoms | Improves (the measure goes down) | 1 study | 20 people |
Type 1 Diabetes
- Glycemic Control: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Glycemic Control | Improves (the measure goes up) | 1 study | 10 people |
Aerobic Exercise Performance
- Aerobic Exercise Metrics: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Aerobic Exercise Metrics | Improves (the measure goes up) | 1 study | 43 people |
Anaerobic Exercise Performance
- Fat Oxidation: improves
- Anaerobic Capacity: worsens
- Glycogen: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Fat Oxidation | Improves (the measure goes up) | 1 study | 16 people | |||
| Anaerobic Capacity Small Detriment | Worsens (the measure goes down) | Small effect | 16 people | |||
| Glycogen | Improves (the measure goes up) | 16 people | ||||
| Oxygen Uptake | Improves (the measure goes up) | 16 people | ||||
| Power Output | Improves (the measure goes up) | 16 people |
Breast Cancer
- DNA methylation: changes; see studies
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| DNA methylation | Changes; see studies | 1 study | 39 people |
Metabolic Health
- Fat Oxidation: improves
- Anaerobic Capacity: worsens
- Glycogen: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Fat Oxidation | Improves (the measure goes up) | 1 study | 16 people | |||
| Anaerobic Capacity Small Detriment | Worsens (the measure goes down) | Small effect | 16 people | |||
| Glycogen | Improves (the measure goes up) | 16 people | ||||
| Oxygen Uptake | Improves (the measure goes up) | 16 people |
Prediabetes
- Glycemic Control: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Glycemic Control | Improves (the measure goes up) | 1 study | 10 people |
Skin Health
- Acne Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Acne Symptoms | Improves (the measure goes down) | 1 study | 20 people |
General Athletic Performance
- Fat Oxidation: improves
- Anaerobic Capacity: worsens
- Glycogen: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Fat Oxidation | Improves (the measure goes up) | 1 study | 16 people | |||
| Anaerobic Capacity Small Detriment | Worsens (the measure goes down) | Small effect | 16 people | |||
| Glycogen | Improves (the measure goes up) | 16 people | ||||
| Oxygen Uptake | Improves (the measure goes up) | 16 people | ||||
| Power Output | Improves (the measure goes up) | 16 people |
What the published studies found
3 automated readings
LDL cholesterol
The best available review (2026, 10 studies) found little or no difference in LDL cholesterol. That review studied patients with type 2 diabetes. 6 of the 7 studies read agree; 1 found an improvement. The evidence is moderate.
7 studies counted of 8 read: 5 reviews and 2 trials (120 people in the trials).
- Meta-analysis, 2026; 10 studies; patients with type 2 diabetes: no clear difference (the review the verdict rests on).
resveratrol supplementation showed only significant effects on LDL-C reduction
The effects of resveratrol on glycemic indices and lipid profile in patients with type 2 diabetes: an umbrella review and meta-analysis - Meta-analysis, 2024: no clear difference. Efficacy of resveratrol supplementation on lipid profile parameters: An umbrella of meta-analysis
- Meta-analysis, 2020; 31 studies; patients with metabolic syndrome and related disorders: no clear difference. The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials
- Meta-analysis, 2015; 6 studies, 196 people: no clear difference.
but not for fasting glucose, homeostatic model assessment of insulin resistance, diastolic blood pressure, insulin, …
Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis - Meta-analysis, 2013; 7 studies, 282 people: no clear difference.
low-density lipoprotein cholesterol (WMD -3.22; 95% CI -12.56-6.12)
Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials - Crossover trial, 2015; 45 people; overweight and slightly obese men and women: no clear difference.
LDL cholesterol -0.03 ± 0.57 mmol/L
Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial - Randomised trial, 2012; 75 people; statin-treated patients in primary cardiovascular disease prevention: improves.
LDLc (-4.5%, p = 0.04), ApoB (-9.8%, p = 0.014), LDLox (-20%, p = 0.001), …
Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial
- Meta-analysis, 2026; 10 studies; patients with type 2 diabetes: no clear difference (the review the verdict rests on).
All-cause mortality
The studies read are too weak to tell whether Resveratrol changes all-cause mortality. The strongest review read studied adults with type 2 diabetes mellitus. The evidence is very weak.
1 study counted of 10 read: 1 review.
- Meta-analysis, 2020; 3 studies, 50 people; adults with type 2 diabetes mellitus: unclear: evidence too weak to tell (the review the verdict rests on).
indicating that no deaths occurred (very low-quality evidence for adverse events, all-cause mortality, and diabetes-related …
Resveratrol for adults with type 2 diabetes mellitus
- Meta-analysis, 2020; 3 studies, 50 people; adults with type 2 diabetes mellitus: unclear: evidence too weak to tell (the review the verdict rests on).
Stress
The studies read are too weak to tell whether Resveratrol changes stress. The evidence is very weak.
5 studies counted of 8 read: 3 reviews and 2 trials (153 people in the trials).
- Meta-analysis, 2024; 6 studies, 533 people: unclear: evidence too weak to tell (the review the verdict rests on). The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis
- Systematic review, 2026; 22 studies; periodontal disease patients and animal models: improves.
improved inflammatory and oxidative stress markers
Contribution of Resveratrol on Periodontal Disease Control and Treatment: A Systematic Review - Systematic review, 2019; 29 studies: improves.
suppressing effects for RSV on the production of AGEs
The impact of resveratrol on toxicity and related complications of advanced glycation end products: A systematic review - Randomised trial, 2025; 56 people; women with polycystic ovary syndrome: improves.
significantly reduced TOS and oxidative stress index
Beneficial Role of Resveratrol on Oxidative Stress in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial - Randomised trial, 2023; 97 people; older adults with type 2 diabetes: improves.
statistically significant increase (p < 0.05) in total antioxidant capacity
Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 Diabetes
Key findings
- Blood glucoseImproves (the measure goes down)
- C-Reactive Protein (CRP)Improves (the measure goes down)
- Blood PressureImproves (the measure goes down)
Shop the evidence-backed picks
Fullscript collectionMetabolic health: evidence-graded picksOpen on Fullscript
The collection holds the supplements we grade A or B for its theme, in third-party tested products where the catalog has them. It opens in our Fullscript store. You can look through it without signing in; Fullscript asks for a free account to order.
Or shop one supplement
Third-party tested Resveratrol products, in the forms the graded studies used where we can match them.
- Grade B
We earn from purchases made in our Fullscript store, and links to Fullscript, iHerb or Thorne carry our referral, so we may earn a commission at no extra cost to you. Grades come from the research and never change based on what we earn. Full disclosure
Studies cited
52 studies from PubMed
- Resveratrol: A Potential Therapeutic Natural Polyphenol for Neurodegenerative Diseases Associated with Mitochondrial Dysfunction
- Resveratrol: An Overview of Clinical Trials in Human Cancer Prevention and Treatment
- Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors
- Resveratrol and Sirtuins: A Story of Living Long Healthy Life
- Therapeutic Potential of Resveratrol in Alzheimer's Disease: A Review of the Evidence
- Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
- Resveratrol and Health - A Comprehensive Review of Human Clinical Trials
- Resveratrol: A Double-Edged Sword in Health Benefits
- Resveratrol and Caloric Restriction: The Role of Sirtuins in Aging and Age-Related Diseases
- The Multitarget Activity of Natural Bioactive Compounds in Parkinson's Disease: Role of Resveratrol
- Resveratrol: A New Treatment for Diseases Associated with Oxidative Stress
- Resveratrol-Based Compounds and Neurodegeneration: Recent Insight in Multitarget Neuroprotection
- An Overview of the Anticancer Properties of Resveratrol
- An Update on Resveratrol and Diabetes: From Metabolism to Clinical Trial Results
- Resveratrol Blunts the Positive Effects of Exercise Training on Cardiovascular Health in Aged Men
- Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease
- The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: A systematic review and meta-analysis.
- Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis.
- Can resveratrol supplement change inflammatory mediators? A systematic review and meta-analysis on randomized clinical trials.
- Resveratrol supplementation efficiently improves endothelial health: A systematic review and meta-analysis of randomized controlled trials.
- Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer
- Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation
- Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients
- The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis.
- Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance
- Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials.
- Resveratrol supplementation and type 2 diabetes: a systematic review and meta-analysis
- Influence of Age and Dose on the Effect of Resveratrol for Glycemic Control in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.
- Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis.
- Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- Efficacy of resveratrol supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials
- The effects of resveratrol supplementation in patients with type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease: an umbrella review of meta-analyses of randomized controlled trials
- Effect of Resveratrol on Blood Lipid Levels in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
- Fine wine or sour grapes? A systematic review and meta-analysis of the impact of red wine polyphenols on vascular health
- The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials.
- Resveratrol supplementation significantly influences obesity measures: a systematic review and dose-response meta-analysis of randomized controlled trials.
- Resveratrol may mildly improve renal function in the general adult population: A systematic review and meta-analysis of randomized controlled clinical trials.
- Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans
- Effects of resveratrol supplementation on liver enzymes: A systematic review and meta-analysis of randomised controlled trials.
- The Effects of Resveratrol Supplementation on Endothelial Function and Blood Pressures Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Resveratrol supplementation does not augment performance adaptations or fibre-type-specific responses to high-intensity interval training in humans
- Resveratrol-containing gel for the treatment of acne vulgaris: a single-blind, vehicle-controlled, pilot study
- Efficacy of Resveratrol Supplementation on Glucose and Lipid Metabolism: A Meta-Analysis and Systematic Review
- Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.
- Effects of resveratrol on polycystic ovarian syndrome: a systematic review and meta-analysis of randomized controlled trials.
- The effect of dietary (poly)phenols on exercise-induced physiological adaptations: A systematic review and meta-analysis of human intervention trials
- Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
- Efficacy and safety of biophenol-rich nutraceuticals in adults with inflammatory gastrointestinal diseases or irritable bowel syndrome: A systematic literature review and meta-analysis
- Effects of resveratrol supplementation on renal function in adults: a systematic review and dose-response meta-analysis.
- Oral resveratrol in adults with knee osteoarthritis: A randomized placebo-controlled trial (ARTHROL).
- Effects of Nasal Solution Incorporating Resveratrol and Carboxymethyl-Β-Glucan in Preschool Non-Atopic Children with Wheezing.
- A Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Impact of Resveratrol Supplementation on Anthropometric Indices in Patients With Type 2 Diabetes.